New approaches to the treatment of sepsis

Clinics in Chest Medicine

Volumn 24, Issue 4, 2003, Pages 521-548

  O'Brien Jr , James M ^a   Abraham, Edward ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CORTICOTROPIN; DOBUTAMINE; DOPAMINE; DROTRECOGIN; ENDOTOXIN ANTIBODY; ETOMIDATE; FENOLDOPAM; FLUDROCORTISONE; HEPARIN; HYDROCORTISONE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NORADRENALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASOACTIVE AGENT; VASOPRESSIN;

ADRENAL DISEASE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; COLLOID; CORTICOSTEROID THERAPY; CRYSTALLOID; ERYTHROCYTE CONCENTRATE; HEALTH CARE COST; HUMAN; INOTROPISM; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0346363154     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00102-3     Document Type: Review

References (267)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29(7):1303-10.
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29(7 Suppl):S109-16.
3. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT I1 Study Group. Lancet 1998;351(9107): 929-33.
4. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277(19):1531-8.
5. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugemier T, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29(3):503-10.
6. Opal SM, Fisher Jr CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase II1, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25(7): 1115-24.
7. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995;274(12):968-74.
8. Wenzel RP. Treating sepsis. N Engl J Med 2002; 347(13):966-7.
9. Wenzel RP, Edmond MB. Severe sepsis-national estimates. Crit Care Med 2001;29(7):1472-4.
10. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113(3):227-42.
11. Niederman MS, Fein AM. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia. A common clinical sequence. Clin Chest Med 1990;11(4):633-56.
12. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340(3):207-14.
13. Pittet D, Thievent B, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 1996;153(2):684-93.
14. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980;68(3): 344-55.
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20(6):864-74.
16. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55.
17. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-709.
18. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7): 862-71.
19. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77.
20. Fisher Jr CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334(26):1697-702.
21. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266(8): 1097-102.
22. Ziegler EJ, Fisher Jr CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324(7): 429-36.
23. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995;23(6):994-1006.
24. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. E5 Study Investigators. JAMA 2000;283(13): 1723-30.
25. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103(5):1536-42.
26. Martinez MA, Pena JM, Fernandez A, Jimenez M, Juarez S, Madero R, et al. Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit Care Med 1999;27(7):1303-8.
27. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24(1):33-44.
28. Levi M, ten Cate H, van der Poll T, van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270(8):975-9.
29. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341(8):586-92.
30. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12(3): 343-59.
31. Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med 2001;29(7 Suppl): S62-7 [discussion S7-8].
32. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996;75(2):224-8.
33. Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998;26(12):2005-9.
34. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101(3):816-23.
35. Opal SM, Thijs LG. New potential therapeutic modalities: antithrombin III. Sepsis 1999;3:153-9.
36. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002;30(5 Suppl):S325-31.
37. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 1985;39(1): 67-9.
38. Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, et al. Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med 2000;26(6):704-15.
39. Jordan RE, Kilpatrick J, Nelson RM. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987;237(4816):777-9.
40. Heyderman RS, Klein NJ, Shennan GI, Levin M. Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb Res 1992;67(6):677-85.
41. Klein NJ, Ison CA, Peakman M, Levin M, Hammerschmidt S, Frosch M, et al. The influence of capsulation and lipooligosaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Neisseria meningitidis. J Infect Dis 1996;173(1):172-9.
42. Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992;102(Pt 4):821-32.
43. Esmon CT. New potential therapeutic modalities: APC. Sepsis 1999;3:161-71.
44. Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica 1999;84(4):363-8.
45. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340(20):1555-64.
46. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986;68(6):1218-23.
47. van Hinsbergh VW, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985;65(2):444-51.
48. Bouma BN, Meijers JC. Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis. Thromb Haemost 1999;82(2):243-50.
49. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek Jr JE, Russell JA, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29(11): 2051-9.
50. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120(3):915-22.
51. Hesselvik JF, Malta J, Dahlback B, Blomback M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991;65(2):126-9.
52. Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78(2): 357-63.
53. Taylor Jr FB, Dahlback B, Chang AC, Lockhart MS, Hatanaka K, Peer G, et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995;86(7): 2642-52.
54. Creasey AA. New potential therapeutics modalities: tissue factor pathway inhibitor. Sepsis 1999;3:173-82.
55. Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29(33):7539-46.
56. Broze Jr GJ, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA 1987;84(7):1886-90.
57. Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-12.
58. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133(2):293-304.
59. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29(11):2081-9.
60. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997;55(4):169-74.
61. Eling M, Stephens AC, Oragui EE, Rivers RP, Levin M. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost 2001;85(2):240-4.
62. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989;61(3):459-62.
63. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999;354(9178): 561-3.
64. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999;354(9178):556-60.
65. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000;28(7):2209-16.
66. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88(3):881-6.
67. Boldt J, Papsdorf M, Rothe A, Kumle B, Piper S. Changes of the hemostatic network in critically ill patients - is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med 2000;28(2): 445-50.
68. Powars D, Larsen R, Johnson J, Hulbert T, Sun T, Patch MJ, et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993;17(2):254-61.
69. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 1993;91(2):418-22.
70. Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994;269(5):3139-42.
71. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000;97(10):5255-60.
72. Carvalho AC, Freeman N. How coagulation defects alter the outcome of sepsis: Survival may depend on reversing the procoagulant conditions. J Crit Illness 1994;9:51-75.
73. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991;77(3):542-50.
74. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79(1):124-30.
75. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73(1):159-65.
76. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997;27(1):3-9.
77. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87(2):642-7.
78. Taoka Y, Okajima K, Uchiba M, Murakami K, Harada N, Johno M, et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J Neurosci 1998;18(4):1393-8.
79. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 1994;4(2): 221-5.
80. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000;83(5):639-43.
81. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor I by the protein C pathway. Science 2002;296(5574):1880-2.
82. Steams-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996;93(19):10212-6.
83. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002;196(5):561-4.
84. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345(6):408-16.
85. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001;29(7 Suppl): S90-4.
86. Taylor Jr FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79(3): 918-25.
87. Taylor Jr FB, Steams-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000;95(5):1680-6.
88. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13(10):818-29.
89. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002;347(13):1030-4.
90. The ARDS Network. A-IA C. FDA Briefing Document. Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)]. BLA#125029/0. Rockville, Maryland: Food and Drug Administration; September 12, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbrie fing.doc. Accessed February 13, 2003.
91. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31(1): 12-9.
92. Ely EW, Bernard GR, Vincent JL. Activated protein C for severe sepsis. N Engl J Med 2002;347(13):1035-6.
93. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002;347(13): 1027-30.
94. Davidson BL, Geerts WH, Lensing AW. Low-dose heparin for severe sepsis. N Engl J Med 2002;347(13):1036-7.
95. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347(13): 993-1000.
96. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31(1):1-11.
97. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995;10(6):321-30.
98. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation 1982;66(5 Pt 2):III56-66.
99. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997;126(1):1-12.
100. Medicare Program. Changes to the hospital inpatient prospective payment systems and fiscal year 2003 rates. Federal Register 2002;67(148):49984.
101. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998;24(1):61-9.
102. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24(1):19-25.
103. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000;28(9 Suppl):S34-7.
104. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286(15):1869-78.
105. Pulletz S, Lehmann C, Volk T, Schmutzler M, Ziemer S, Kox WJ, et al. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 2000;28(8):2881-6.
106. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93(1):157-64.
107. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;163(3):1404-11.
108. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59(6):895-904.
109. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998;89(5):233-41.
110. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270(6 Pt 1):L921-30.
111. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000;28(9 Suppl):S31-3.
112. Chiron announces results of Phase III Study of tifacogin in severe sepsis. Available at: http://www.chiron. com/investor/news/index.htm). Accessed February 13, 2003.
113. Review committee recommends termination of phase 3 study of pafase - rPAF-AH - in severe sepsis. ICOS Corporation. Available at: http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=ICOS&script= 410&layout=0&item_id=365376). Accessed February 13, 2003.
114. Corrigan Jr JJ. Heparin therapy in bacterial septicemia. J Pediatr 1977;91(5):695-700.
115. Hahn EO, Houser HB, Rammelkamp CH. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. J Clin Invest 1951;30:274-81.
116. Packard BD, Weiler JM. Steroids inhibit activation of the alternative-amplification pathway of complement. Infect Immun 1983;40(3):1011-4.
117. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329(27):2002-12.
118. Skubitz KM, Craddock PR, Hammerschmidt DE, August JT. Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro. J Clin Invest 1981;68(1):13-20.
119. Dhainaut JF, Mira JP, Fierobe L. Platelet activating factor: pathophysiological changes and therapeutic implications in sepsis. In: Reinhart K, Eyrich K, Sprung C, editors. Update in intensive care and emergency medicine. Berlin: Springer-Verlag; 1994. p. 397-413.
120. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986;232(4753):977-80.
121. Parant M, Le Contel C, Parant F, Chedid L. Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res 1991;10(4):265-71.
122. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982;129(5):1803-5.
123. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979;278(5703):456-9.
124. Hinshaw LB, Archer LT, Beller-Todd BK, Coalson JJ, Flournoy DJ, Passey R, et al. Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res 1980;28(2):151-70.
125. Bennett IL, Finland M, Hamburger M. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963;183:462-5.
126. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184(3):333-41.
127. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984;311(18):1137-43.
128. Bone RC, Fisher Jr CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317(11): 653-8.
129. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317(11): 659-65.
130. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23(7):1294-303.
131. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23(8):1430-9.
132. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983;1(8336):1270.
133. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984;39(10):973-81.
134. de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984;59(6):1143-7.
135. Rothwell PM, Udwadia ZF, Jackson EA, Lawler PJ. Plasma cortisol levels in patients with septic shock. Crit Care Med 1991;19(4):589-90.
136. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337(8741):582-3.
137. Soni A, Pepper GM, Wyrwinski PM, Ramirez NE, Simon R, Pina T, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98(3):266-71.
138. Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997;337(18):1285-92.
139. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283(8): 1038-45.
140. Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael JC, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46(6):589-97.
141. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000;68(3):293-303.
142. Bhagat K, Collier J, Vallance P. Local venous responses to endotoxin in humans. Circulation 1996;94(3):490-7.
143. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26(4):645-50.
144. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27(4):723-32.
145. Briegel J, Forst H, Kellermann W, Haller M, Peter K. Haemodynamic improvement in refractory septic shock with cortisol replacement therapy. Intensive Care Med 1992;18(5):318.
146. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270(24):2957-63.
147. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003;31(1):141-5.
148. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345(19):1359-67.
149. McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983;1(8322):484.
150. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150(5):1999-2006.
151. Zipser RD, Davenport MW, Martin KL, Tuck ML, Warner NE, Swinney RR, et al. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. J Clin Endocrinol Metab 1981;53(4):867-73.
152. Findling JW, Waters VO, Raff H. The dissociation of renin and aldosterone during critical illness. J Clin Endocrinol Metab 1987;64(3):592-5.
153. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA 1994;271(3):226-33.
154. Rady MY, Rivers EP, Nowak RM. Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med 1996;14(2): 218-25.
155. Cortez A, Zito J, Lucas CE, Gerrick SJ. Mechanism of inappropriate polyuria in septic patients. Arch Surg 1977;112(4):471-6.
156. Elliott DC. An evaluation of the end points of resuscitation. J Am Coll Surg 1998;187(5):536-47.
157. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995;333(16):1025-32.
158. Bland RD, Shoemaker WC, Abraham E, Cobo JC. Hemodynamic and oxygen transport patterns in surviving and nonsurviving postoperative patients. Crit Care Med 1985;13(2):85-90.
159. Shoemaker WC, Appel PL, Kram HB. Hemodynamic and oxygen transport responses in survivors and non-survivors of high-risk surgery. Crit Care Med 1993;21(7):977-90.
160. Shoemaker WC, Appel PL, Kram HB, Bishop MH, Abraham E. Temporal hemodynamic and oxygen transport patterns in medical patients. Septic shock. Chest 1993;104(5):1529-36.
161. Shoemaker WC, Appel PL, Kram HB, Bishop MH, Abraham E. Sequence of physiologic patterns in surgical septic shock. Crit Care Med 1993;21(12): 1876-89.
162. Edwards JD, Brown GC, Nightingale P, Slater RM, Faragher EB. Use of survivors' cardiorespiratory values as therapeutic goals in septic shock. Crit Care Med 1989;17(11):1098-103.
163. Gilbert EM, Haupt MT, Mandanas RY, Huaringa AJ, Carlson RW. The effect of fluid loading, blood transfusion, and catecholamine infusion on oxygen delivery and consumption in patients with sepsis. Am Rev Respir Dis 1986;134(5):873-8.
164. Heyland DK, Cook DJ, King D, Kernerman P, Brun-Buisson C. Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Crit Care Med 1996;24(3):517-24.
165. Kern JW, Shoemaker WC. Meta-analysis of hemodynamic optimization in high-risk patients. Crit Care Med 2002;30(8):1686-92.
166. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330(24):1717-22.
167. Pulmonary Artery Catheter Consensus Conference. Consensus statement. Crit Care Med 1997;25(6): 910-25.
168. Sandham JD, Hull RD, Brant RF. Pulmonary artery flow directed catheter: the evidence. Lancet 1996;348(9038):1324.
169. Sandham JD, Hull RD, Brant RF. The pulmonary artery catheter takes a great fall. Crit Care Med 1998;26(7):1288-9.
170. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348(1):5-14.
171. Connors Jr AF, Speroff T, Dawson NV, Thomas C, Harrell Jr FE, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996;276(11):889-97.
172. Iberti TJ, Daily EK, Leibowitz AB, Schecter CB, Fischer EP, Silverstein JH. Assessment of critical care nurses' knowledge of the pulmonary artery catheter. The Pulmonary Artery Catheter Study Group. Crit Care Med 1994;22(10):1674-8.
173. Iberti TJ, Fischer EP, Leibowitz AB, Panacek EA, Silverstein JH, Albertson TE. A multicenter study of physicians' knowledge of the pulmonary artery catheter. Pulmonary Artery Catheter Study Group. JAMA 1990;264(22):2928-32.
174. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001;120(6):2059-93.
175. Albert RK, Condie F. Hand-washing patterns in medical intensive-care units. N Engl J Med 1981;304(24): 1465-6.
176. Goldmann D, Larson E. Hand-washing and nosocomial infections. N Engl J Med 1992;327(2):120-2.
177. Jarvis WR. Handwashing - the Semmelweis lesson forgotten? Lancet 1994;344(8933):1311-2.
178. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17(1):53-80.
179. Gerding DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000;21(1 Suppl):S12-7.
180. Manthous CA. Toward a more thoughtful approach to fever in critically ill patients. Chest 2000;117(3): 627-8.
181. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274(8): 639-44.
182. Pittet D, Harbarth S, Ruef C, Francioli P, Sudre P, Petignat C, et al. Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. Infect Control Hosp Epidemiol 1999;20(1): 37-42.
183. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: The effect of body position. Ann Intern Med 1992;116(7):540-3.
184. Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. Chest 1999;116(5):1339-46.
185. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333(13):817-22.
186. Guerin C, Girard R, Chemorin C, De Varax R, Fournier G. Facial mask noninvasive mechanical ventilation reduces the incidence of nosocomial pneumonia. A prospective epidemiological survey from a single 1CU. Intensive Care Med 1997;23(10):1024-32.
187. Kollef MH, Shapiro SD, Silver P, St John RE, Prentice D, Sauer S, et al. A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Crit Care Med 1997;25(4):567-74.
188. Ely EW, Baker AM, Dunagan DP, Burke HL, Smith AC, Kelly PT, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996;335(25):1864-9.
189. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342(20):1471-7.
190. Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999;27(12):2609-15.
191. Holzapfel L, Chastang C, Demingeon G, Bohe J, Piralla B, Coupry A. A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients. Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1999;159(3):695-701.
192. Talmor M, Li P, Barie PS. Acute paranasal sinusitis in critically ill patients: guidelines for prevention, diagnosis, and treatment. Clin Infect Dis 1997;25(6): 1441-6.
193. Darouiche RO. Prevention of vascular catheter-related infections. Neth J Med 1999;55(3):92-9.
194. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999;340(1): 1-8.
195. Heard SO, Wagle M, Vijayakumar E, McLean S, Brueggemann A, Napolitano LM, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 1998;158(1):81-7.
196. Randolph AG. An evidence-based approach to central venous catheter management to prevent catheter-related infection in critically ill patients. Crit Care Clin 1998;14(3):411-21.
197. Randolph AG, Cook DJ, Gonzales CA, Brun-Buisson C. Tunneling short-term central venous catheters to prevent catheter-related infection: a meta-analysis of randomized, controlled trials. Crit Care Med 1998;26(8):1452-7.
198. Timsit JF, Bruneel F, Cheval C, Mamzer MF, Garrouste-Orgeas M, Wolff M, et al. Use of tunneled femoral catheters to prevent catheter-related infection. A randomized, controlled trial. Ann Intern Med 1999;130(9):729-35.
199. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282(6):554-60.
200. Pearson ML. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17(7):438-73.
201. Ehrenkranz NJ, Shultz JM, Richter EL. Recorded criteria as a "gold standard" for sensitivity and specificity estimates of surveillance of nosocomial infection: a novel method to measure job performance. Infect Control Hosp Epidemiol 1995;16(12):697-702.
202. Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Bruso PA, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994;15(4 Pt 1):231-8.
203. Parrillo JE. Cardiovascular dysfunction in human septic shock. Prog Clin Biol Res 1989;308:191-9.
204. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97(3):713-9.
205. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, et al. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J Clin Invest 1997;99(7):1516-24.
206. Abraham E, Kaneko DJ, Shenkar R. Effects of endogenous and exogenous catecholamines on LPS-induced neutrophil trafficking and activation. Am J Physiol 1999;276(1 Pt 1):L1-8.
207. Arcaroli J, Yang KY, Yum HK, Kupfner J, Pitts TM, Park JS, et al. Effects of catecholamines on kinase activation in lung neutrophils after hemorrhage or endotoxemia. J Leukoc Biol 2002;72(3):571-9.
208. Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103(6):1826-31.
209. Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28(8):2758-65.
210. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272(17):1354-7.
211. Day NP, Phu NH, Bethell DP, Mai NT, Chau TT, Hien TT, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996;348(9022): 219-23.
212. Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG. Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Emphasis on right ventricular performance. Chest 1989;95(6):1282-8.
213. Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997;23(3):282-7.
214. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997;25(3):399-404.
215. Desjars P, Pinaud M, Bugnon D, Tasseau F. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989;17(5): 426-9.
216. Marin C, Eon B, Saux P, Aknin P, Gouin F. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18(3):282-5.
217. Redl-Wenzl EM, Armbruster C, Edelmann G, Fischl E, Kolacny M, Wechsler-Fordos A, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19(3):151-4.
218. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345(8):588-95.
219. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120(3):989-1002.
220. Landry DW, Levin HR, Gallant EM, Ashton Jr RC, Seo S, D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95(5):1122-5.
221. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30(3):497-500.
222. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001;93(1):7-13.
223. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27(8):1416-21.
224. Malay MB, Ashton Jr RC, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47(4):699-703 [discussion 703-5].
225. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96(3): 576-82.
226. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle III WA. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29(3): 487-93.
227. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356(9248):2139-43.
228. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 1996;101(1):49-53.
229. Galley HF. Renal-dose dopamine: will the message now get through? Lancet 2000;356(9248):2112-3.
230. Girbes AR, Patten MT, McCloskey BV, Groeneveld AB, Hoogenberg K. The renal and neurohumoral effects of the addition of low-dose dopamine in septic critically ill patients. Intensive Care Med 2000;26(11): 1685-9.
231. Kellum JA, Bellomo R. Low-dose dopamine: what benefit? Crit Care Med 2000;28(3):907-8.
232. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29(8):1526-31.
233. Lherm T, Troche G, Rossignol M, Bordes P, Zazzo JF. Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med 1996;22(3):213-9.
234. Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med 1999;107(4):387-90.
235. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50(1):4-14.
236. Halpenny M, Markos F, Snow HM, Duggan PF, Gaffney E, O'Connell DP, et al. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs. Crit Care Med 2001;29(4): 855-60.
237. Holcslaw TL, Beck TR. Clinical experience with intravenous fenoldopam. Am J Hypertens 1990;3(6 Pt 2): 120S-5S.
238. Madyoon H, Croushore L. Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory: a case series. J Interv Cardiol 2001;14(2):179-85.
239. Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann J, McGuire D, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999;27(9):1832-7.
240. Nichols AJ, Ruffolo Jr RR, Brooks DP. The pharmacology of fenoldopam. Am J Hypertens 1990;3(6 Pt 2): 116S-9S.
241. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998;31(5):743-55.
242. Aurora RN, Milite F, Carlon G. Preventing renal failure in critically ill patients. Crit Care Med 1999;27(9): 2044-5.
243. Gilbert TB, Hasnain JU, Flinn WR, Lilly MP, Benjamin ME. Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther 2001;6(1):31-6.
244. Halpenny M, Lakshmi S, O'Donnell A, O'Callaghan-Enright S, Shorten GD. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001;56(10): 953-60.
245. Halpenny M, Rushe C, Breen P, Cunningham AJ, Boucher-Hayes D, Shorten GD. The effects of fenol-dopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2002;19(1): 32-9.
246. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336(13):912-8.
247. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342(18):1301-8.
248. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. Report of the American-European Consensus Conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994;9(1):72-81.
249. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3 Pt 1): 818-24.
250. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. Report of the American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994;20(3):225-32.
251. 2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group. Chest 1989;96(4):849-51.
252. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996;334(22):1417-21.
253. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002;30(1): 1-6.
254. The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000;283(15):1995-2002.
255. Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, et al. Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 2000;28(10):3405-11.
256. Wheeler A, Carmichael LC, Christman BW. Renal function abnormalities in sepsis. Am J Respir Crit Care Med 1995;151(Suppl):A317.
257. Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl 1998;66:S16-24.
258. Liano F, Pascual J. Outcomes in acute renal failure. Semin Nephrol 1998;18(5):541-50.
259. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334(22):1448-60.
260. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346(5):305-10.
261. Bonventre JV. Daily hemodialysis - will treatment each day improve the outcome in patients with acute renal failure? N Engl J Med 2002;346(5):362-4.
262. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186(10):1522-5.
263. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27(7):1330-4.
264. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999;282(6):561-8.
265. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001;29(3):557-61.
266. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24(3):381-4.
267. Rubenfeld GD, Angus DC, Pinsky MR, Curtis JR, Connors Jr AF, Bernard GR. Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. The Members of the Outcomes Research Workshop. Am J Respir Crit Care Med 1999;160(1): 358-67.